WO2010140339A1 - Composé hétérocyclique - Google Patents

Composé hétérocyclique Download PDF

Info

Publication number
WO2010140339A1
WO2010140339A1 PCT/JP2010/003640 JP2010003640W WO2010140339A1 WO 2010140339 A1 WO2010140339 A1 WO 2010140339A1 JP 2010003640 W JP2010003640 W JP 2010003640W WO 2010140339 A1 WO2010140339 A1 WO 2010140339A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituent
group
hydrogen atom
independently represent
compound
Prior art date
Application number
PCT/JP2010/003640
Other languages
English (en)
Japanese (ja)
Inventor
望月倫代
今枝稔博
Original Assignee
武田薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 武田薬品工業株式会社 filed Critical 武田薬品工業株式会社
Publication of WO2010140339A1 publication Critical patent/WO2010140339A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet un nouvel amplificateur de la fonction du récepteur AMPA. La présente invention concerne spécifiquement un composé représenté par la formule (Io) [Y ou Z représentant un atome d'azote ou un atome d'oxygène et l'autre représentant un atome de carbone; R1a, R1b, R4a et R4b étant indépendamment non présents ou bien représentant indépendamment un atome d'hydrogène ou un substituant; R2a, R2b, R3a et R3b représentant indépendamment un atome d'hydrogène ou un substituant; R5 représentant un substituant; et Ar représentant un cycle benzène ou un cycle hétérocyclique aromatique monocyclique, chacun pouvant être substitué; lorsque le cycle benzène ou le cycle hétérocyclique aromatique monocyclique est substitué par deux substituants ou plus, deux des substituants pouvant former ensemble un cycle qui peut être substitué] ou son sel.
PCT/JP2010/003640 2009-06-01 2010-05-31 Composé hétérocyclique WO2010140339A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-132128 2009-06-01
JP2009132128 2009-06-01

Publications (1)

Publication Number Publication Date
WO2010140339A1 true WO2010140339A1 (fr) 2010-12-09

Family

ID=43297482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/003640 WO2010140339A1 (fr) 2009-06-01 2010-05-31 Composé hétérocyclique

Country Status (1)

Country Link
WO (1) WO2010140339A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575154B2 (en) 2010-08-10 2013-11-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9493484B2 (en) 2012-02-08 2016-11-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2019070044A1 (fr) 2017-10-06 2019-04-11 武田薬品工業株式会社 Composés hétérocycliques
WO2019070043A1 (fr) 2017-10-06 2019-04-11 武田薬品工業株式会社 Composé hétérocyclique

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59106490A (ja) * 1982-11-26 1984-06-20 バイエル・アクチエンゲゼルシヤフト ピラノ−ピラゾ−ル誘導体
JP2005517644A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 環縮合したピラゾール誘導体
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
JP2006526003A (ja) * 2003-05-30 2006-11-16 エフ．ホフマン−ラ　ロシュ　アーゲー ベンゾチアゾール誘導体、およびアデノシンａ２ａ受容体に関連した疾患の処置でのその使用
WO2007107539A1 (fr) * 2006-03-20 2007-09-27 Glaxo Group Limited Composés qui potentialisent le récepteur ampa et leurs utilisations en médicine
WO2008024978A2 (fr) * 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
JP2008524330A (ja) * 2004-12-21 2008-07-10 シェーリング コーポレイション ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト
JP2008538772A (ja) * 2005-04-25 2008-11-06 ハー・ルンドベック・アクチエゼルスカベット Ｎ−チアゾール−２−イル−ベンズアミド誘導体のプロドラッグ
WO2009073777A1 (fr) * 2007-12-06 2009-06-11 Schering Corporation Modulateurs de la gamma sécrétase

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59106490A (ja) * 1982-11-26 1984-06-20 バイエル・アクチエンゲゼルシヤフト ピラノ−ピラゾ−ル誘導体
JP2005517644A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 環縮合したピラゾール誘導体
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
JP2006526003A (ja) * 2003-05-30 2006-11-16 エフ．ホフマン−ラ　ロシュ　アーゲー ベンゾチアゾール誘導体、およびアデノシンａ２ａ受容体に関連した疾患の処置でのその使用
JP2008524330A (ja) * 2004-12-21 2008-07-10 シェーリング コーポレイション ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト
JP2008538772A (ja) * 2005-04-25 2008-11-06 ハー・ルンドベック・アクチエゼルスカベット Ｎ−チアゾール−２−イル−ベンズアミド誘導体のプロドラッグ
WO2007107539A1 (fr) * 2006-03-20 2007-09-27 Glaxo Group Limited Composés qui potentialisent le récepteur ampa et leurs utilisations en médicine
WO2008024978A2 (fr) * 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
WO2009073777A1 (fr) * 2007-12-06 2009-06-11 Schering Corporation Modulateurs de la gamma sécrétase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DP JINDAL ET AL.: "Synthesis and anti- inflammatory activity of 2'-phenyl steroidal [17,16-c]pyrazoles", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 6, 1991, pages 651 - 654, XP023870513, DOI: doi:10.1016/0223-5234(91)90201-W *
R GUPTA ET AL.: "Synthesis and biological activity of azasteroidal [3,2-c]- and [17,16-c]pyrazoles", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 3, 1996, pages 241 - 247, XP004040112, DOI: doi:10.1016/0223-5234(96)89140-9 *
VITTORIA COLOTTA ET AL.: "Synthesis and Al and A2A adenosine binding activity of some pyrano [2,3-c]pyrazol-4-ones", FARMACO, vol. 53, no. 3, 1998, pages 189 - 196 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654874B2 (en) 2010-08-10 2020-05-19 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8778934B2 (en) 2010-08-10 2014-07-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8916551B2 (en) 2010-08-10 2014-12-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9150591B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8575154B2 (en) 2010-08-10 2013-11-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9499568B2 (en) 2010-08-10 2016-11-22 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9884875B2 (en) 2010-08-10 2018-02-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11279713B2 (en) 2010-08-10 2022-03-22 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9493484B2 (en) 2012-02-08 2016-11-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2019070043A1 (fr) 2017-10-06 2019-04-11 武田薬品工業株式会社 Composé hétérocyclique
EP3693360A4 (fr) * 2017-10-06 2021-02-17 Takeda Pharmaceutical Company Limited Composés hétérocycliques
EP3693368A4 (fr) * 2017-10-06 2021-02-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2019070044A1 (fr) 2017-10-06 2019-04-11 武田薬品工業株式会社 Composés hétérocycliques
US11407748B2 (en) 2017-10-06 2022-08-09 Takeda Pharmaceutical Company Limited Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US11939327B2 (en) 2017-10-06 2024-03-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Similar Documents

Publication Publication Date Title
US11279713B2 (en) Heterocyclic compound and use thereof
US9527807B2 (en) Sulfonamide derivative and use thereof
AU2018338855B2 (en) Heterocyclic compound
JPWO2009119088A1 (ja) 複素環化合物
RU2677697C1 (ru) Производные триазолопиридина в качестве модуляторов активности tnf
WO2011036889A1 (fr) Composé hétérocyclique
JPWO2011093352A1 (ja) チアゾール誘導体
WO2010140339A1 (fr) Composé hétérocyclique
WO2011036885A1 (fr) Composé hétérocyclique
WO2019151269A1 (fr) Composé hétérocyclique
JP6134654B2 (ja) 複素環化合物およびその用途
JPWO2013100018A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10783127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10783127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP